Actinium Pharmaceuticals (OTCQB:ATNM) is a cancer-focused biotech that is fundamentally misunderstood due to a perfect storm of "valuation limiting" factors that provide a classic low risk/high reward investment opportunity. The current valuation does not accurately reflect the significant potential licensing opportunities or attractiveness to a larger acquirer given the current M&A environment.
ATNM focuses on the development of cancer drugs based on its proprietary Alpha Particle Immunotherapy platform, which is potentially applicable to a wide variety of cancers. This is a highly potent and selective form of targeted radiotherapy, in which powerful alpha emitting radioisotopes (Actinium 225* or Bismuth 213) are carried by monoclonal antibodies (mAbs) directly to cancer cells.
ATNM has two clinical stage drugs:...
Only subscribers can access this article, which is part of the PRO research library covering 3,584 different stocks.
Growing numbers of fund managers and other investment professionals subscribe to Seeking Alpha PRO for equity research that is unavailable elsewhere, so they can: